Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $25,082,296.44 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 483,654 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total value of $25,082,296.44. Following the transaction, the chief executive officer owned 431,904 shares of the company’s stock, valued at $22,398,541.44. This represents a 52.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA opened at $55.27 on Friday. The stock has a market capitalization of $4.23 billion, a PE ratio of 61.41 and a beta of 0.17. The business has a 50 day simple moving average of $46.40 and a two-hundred day simple moving average of $43.16. Kiniksa Pharmaceuticals International, plc has a 1-year low of $24.85 and a 1-year high of $55.28.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.11 EPS. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently modified their holdings of KNSA. Qube Research & Technologies Ltd boosted its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after purchasing an additional 447,536 shares during the period. Spruce Street Capital LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $17,943,000. Finally, SG Americas Securities LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 288.6% during the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after acquiring an additional 402,078 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (?+55% YoY); management raised FY?2026 revenue guidance, improving near?term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL?387 Phase?2 readout (recurrent pericarditis) is expected 2H?2026 with a planned Phase?3 start by year?end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre?arranged 10b5?1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short?term negative sentiment despite being pre?planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5?1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Wall Street Analysts Forecast Growth

KNSA has been the subject of several research analyst reports. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Wednesday. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.